CARLSBAD, Calif., Feb. 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences:
A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. The replay will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.
| Last Trade: | US$70.86 |
| Daily Change: | -0.64 -0.90 |
| Daily Volume: | 1,978,078 |
| Market Cap: | US$11.290B |
October 07, 2025 September 22, 2025 September 19, 2025 September 09, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
